CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Mezzion Pharma Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Mezzion Pharma Co Ltd
3F, C&H Bldg
35, Teheranro 87-Gil, Gangnam-Gu
Phone: +82 25608000p:+82 25608000 SEOUL, 06163  South Korea Ticker: 140410140410
Business Summary
Mezzion Pharma Co., Ltd. is a Korea-based company engaged in the pharmaceutical business. The Company focuses on development and manufacture of remedies for erectile dysfunction and benign prostatic hyperplasia. In addition, the Company engages in the development of remedies for portal hypertension (PH), pulmonary arterial hypertension (PAH), overactive bladder (OAB), chronic obstructive pulmonary disease (COPD) and others. The Company has sighed licensing contract with overseas partners, including Warner in America, Valenta in Russia, Nycomed in Mexico and Dr.Falk in Europe. On April 22, 2013, the Company changed its name from Dong-A Pharmtech Co., Ltd. to Mezzion Pharma Co., Ltd.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2048 Prepared feeds and feed ingredients for animals and fowls, except dog and cat

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director Dong HyeonPark 67
Director Beom JinChoi 54 3/26/2024 3/26/2024
Director Peter J.Manso 67
3 additional Officers and Directors records available in full report.

Business Names
Business Name
140410
Mezzion Pharma Co.,Ltd.

General Information
Number of Employees: 24 (As of 12/31/2015)
Outstanding Shares: 29,963,337 (As of 10/31/2024)
Shareholders: 33,523
Stock Exchange: KDQ
Fax Number: +82 25636517


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024